The European Medicines Agency (EMA) is evaluating experimental treatments that were developed in Japan.
1 report, 1 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency (EMA) is evaluating experimental treatments that were developed in Japan.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Nuvation Bio Inc. observed therapeutic responses in trials and is conducting a Phase 2 J201 study in Japan for its drug Safusidenib.Sub-event
EMA is evaluating experimental treatments developed in Japan.1 source
Keep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.